Free tool · No account
Clinical trials for bladder cancer
Bladder cancer trials differ between early, non-muscle-invasive disease and advanced disease, with immunotherapy and antibody-drug conjugates prominent in the advanced setting.
518 recruiting trials. Showing a sample.
- recruitingNCT04900558
Robotic Radical Cystectomy Outcomes
Currently, in the treatment of bladder cancer the use of robotics has entered in clinical practice, therefor robotic radical cystectomy with or without reconstruction is offered to patients during counseling procedures, if deemed appropriate and possible. The aim of the study ...
Listed by the study for Bladder Cancer. Record updated 2021-05-25.
Sponsored by University of FlorenceFull details on ClinicalTrials.gov → - recruitingNCT07130578
The Guiding Value of Liquid Biopsy Based on Urinary Tumor DNA/RNA in the Second Transurethral Resection of High-risk Non-muscle Invasive Bladder Cancer
High-risk non-muscle-invasive bladder cancer (NMIBC) carries a substantial risk of residual disease after initial transurethral resection of bladder tumor (TURBT). Current guidelines recommend a second TURBT (re-TURBT) within 2-6 weeks for patients with stage T1 disease to rem...
Listed by the study for Bladder Cancer. Record updated 2026-03-03.
Sponsored by Tianjin Medical University Second HospitalFull details on ClinicalTrials.gov → - recruitingPhase 2NCT04724928
Evaluating the Impact of 18F-FDG-PET-CT on Risk Stratification and Treatment Adaptation for Patients with Muscle Invasive Bladder Cancer
Evaluate the impact of 18F-FDG-PET-CT on the staging of patients with muscle invasive bladder cancer. Based on the results of 2 18F-FDG-PET-CT's patients are stratified in non-metastatic, oligometastatic and polymetastatic bladder cancer patients and the treatment is adapted a...
Listed by the study for Muscle-Invasive Bladder Carcinoma. Record updated 2025-01-15.
Sponsored by University Hospital, GhentFull details on ClinicalTrials.gov → - recruitingPhase 1, Phase 2NCT07122414
A Study of Intravesical FL115 Alone or in Combination With BCG in Non-Muscle Invasive Bladder Cancer
The study is to evaluate the safety and tolerability of intravesical FL115 alone or in combination with BCG in the patients with NMIBC, and to determine the RP2D of FL115 in combination with BCG. To evaluate the preliminary efficacy of FL115 alone or in combination with BCG i...
Listed by the study for Non-muscle Invasive Bladder Cancer (NMIBC). Record updated 2025-08-14.
Sponsored by Suzhou Forlong Biotechnology Co., LtdFull details on ClinicalTrials.gov → - recruitingNANCT04916990
Improving Care for Rural Patients With Solid Tumors
This study will assess if the CARES (Cancer Advocacy, Resources, Education and Support) intervention improves time to start of treatment after diagnosis and time to treatment completion for solid tumors (ex: lung, head, neck, thyroid, cervical, breast, bladder, colon, and rect...
Listed by the study for Bladder Cancer. Record updated 2026-02-05.
Sponsored by University of Colorado, DenverFull details on ClinicalTrials.gov → - recruitingPhase 1NCT05176483
Study of Zanzalintinib in Combination With Immuno-Oncology or Other Agents in Participants With Solid Tumors
This is a multicenter Phase 1b, open label, dose-escalation and cohort-expansion study, evaluating the safety, tolerability, pharmacokinetics (PK), preliminary antitumor activity, and effect of biomarkers of zanzalintinib administered alone, and in combination with nivolumab (...
Listed by the study for Urothelial Carcinoma (UC). Record updated 2026-10-01.
Sponsored by ExelixisFull details on ClinicalTrials.gov → - recruitingPhase 1NCT07623369
A First-in-Human Study of HH160 in Participants With Advanced or Metastatic Solid Tumors
This study is evaluating the safety, side effects, how the body processes HH160, and its early anticancer activity when given alone or with other cancer treatments in participants with advanced solid tumors. The study will also identify the recommended dose for future studies....
Listed by the study for Urothelial Carcinoma. Record updated 2026-08-21.
Sponsored by Huahui HealthFull details on ClinicalTrials.gov → - recruitingNANCT07164950
Compression Stockings to Prevent Peripheral Neuropathy Caused by Antibody-Drug Conjugates in Urothelial Carcinoma Patients
This multicenter, prospective phase II clinical trial aims to evaluate the efficacy and safety of medical compression stockings in preventing peripheral neuropathy induced by antibody-drug conjugates (ADCs) containing monomethyl auristatin E (MMAE) in patients with advanced ca...
Listed by the study for Urothelial Carcinoma. Record updated 2025-09-15.
Sponsored by Sheng ZhangFull details on ClinicalTrials.gov → - recruitingPhase 1, Phase 2NCT04977453
GI-101/GI-101A as a Single Agent or in Combination With Pembrolizumab or Lenvatinib in Advanced Solid Tumors
The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics, and therapeutic activity of GI-101/GI-101A as a single agent or in combination with pembrolizumab or lenvatinib over a range of advanced and/or metastatic solid tumors.
Listed by the study for Urothelial Carcinoma. Record updated 2026-10-19.
Sponsored by GI Innovation, Inc.Full details on ClinicalTrials.gov → - recruitingPhase 3NCT07498907
Disitamab Vedotin Plus Radiotherapy for Adjuvant Treatment of HER2-Expressing Cisplatin-Ineligible Upper Tract Urothelial Carcinoma
This randomized, open-label, multicenter phase III study is designed to compare disitamab vedotin plus radiotherapy with gemcitabine plus carboplatin as adjuvant treatment in patients with HER2-expressing upper tract urothelial carcinoma after radical nephroureterectomy (RNU)....
Listed by the study for Upper Tract Urothelial Carcinoma. Record updated 2026-09-28.
Sponsored by Peking University First HospitalFull details on ClinicalTrials.gov →
Data from ClinicalTrials.gov, retrieved 2026-11-14. Study sponsors write and update their own records there, including the recruitment status shown here, and the U.S. government does not review or approve every study listed. A trial showing up here is not a recommendation and not a determination that anyone qualifies. Eligibility is decided by the trial's own doctors.
Refine for your situation
Add whatever you know: an age, a city, a mutation from a pathology report. We'll narrow the list to trials that fit. Describe it in your own words.
Trials for other conditions
What we will never do with your records
This generator runs without an account, and KeptWell itself makes the same promises to every family, regardless of plan or price.
- We won't sell your data.
- Not to advertisers, not to data brokers, not to insurers, not to pharma, not to anyone, in any form, ever.
- We won't train AI models on your records.
- KeptWell does not opt in to model training. OpenAI and Anthropic do not use API inputs or outputs to train their models by default.
- We won't lock you in.
- You can export everything in your circle as a ZIP at any time. Cancellation is one click.
Common questions
- Is this bladder cancer trial finder really free?
- Yes. You describe the situation, we search ClinicalTrials.gov and show what matches. No account, no payment, no email required. Nothing you type is saved.
- Does showing up here mean the patient qualifies?
- No. A listing here is not a recommendation, and the U.S. government does not review or approve every study on ClinicalTrials.gov. These are trials worth asking your care team about. Every trial has detailed eligibility criteria that the trial's own doctors evaluate, and many depend on test results and treatment history that only your medical team knows in full.
- How current is this list?
- The trials come directly from ClinicalTrials.gov and are refreshed daily, with the retrieval date shown under the list. Each study record is written and kept up to date by that study's own sponsor, so the recruitment status is what the sponsor last reported. Each result links to the full, live record, and the finder above always runs a fresh search when you use it.
- What should I do with a trial that looks promising?
- Bring it to your oncologist or care team, and mention the NCT number (the ID that starts with NCT). They can tell you whether it is a genuine fit and refer you to the trial site.
Found trials worth discussing? Keep them next to the records.
The next step is a conversation with the care team, and that goes better when the scans, labs, and trial details live in one place everyone in the family can see. That's what KeptWell is: the binder, but it understands what's inside.
Get started
We'll email you a secure sign-in link. It works whether you're new here or already have an account.